Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial

Krishna Mohan Vadrevu, Brunda Ganneru, Siddharth Reddy, Harsh Jogdand, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Raches Ella, Priya Abraham, Sai Prasad, Krishna Ella
doi: https://doi.org/10.1101/2022.01.05.22268777

Article usage

Article usage: January 2022 to October 2024

AbstractFullPdf
Jan 20226898381619
Feb 202243430142
Mar 20223271492
Apr 20222711590
May 2022236878
Jun 2022174642
Jul 2022193625
Aug 20221051232
Sep 2022841046
Oct 202276835
Nov 202245118
Dec 2022116328
Jan 202354427
Feb 202343418
Mar 202358817
Apr 202361316
May 202337712
Jun 202376611
Jul 202348414
Aug 2023331411
Sep 202338911
Oct 20236159
Nov 20233892
Dec 202328413
Jan 20241842
Feb 202427714
Mar 20242656
Apr 202430810
May 20242057
Jun 202428810
Jul 202427513
Aug 2024441132
Sep 202443612
Oct 2024861
Back to top
Posted January 08, 2022.
Download PDF
Data/Code
Email
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
Krishna Mohan Vadrevu, Brunda Ganneru, Siddharth Reddy, Harsh Jogdand, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Raches Ella, Priya Abraham, Sai Prasad, Krishna Ella
medRxiv 2022.01.05.22268777; doi: https://doi.org/10.1101/2022.01.05.22268777
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area